Talin1 and Rap1 Are Critical for Osteoclast Function

T
he osteoclast is the principal, if not exclusive, skeletal resorptive cell whose activity is initiated by contact with bone. In all cells, including osteoclasts, integrins recognize substrate, participate in cytoskeletal organization, and transmit matrix-derived signals, events essential to the resorptive process (1, 2) .
␣v␤3 is the principal integrin mediating the osteoclast's capacity to resorb bone. This heterodimer remodels the cell's cytoskeleton via recruitment of a complex including c-Src, Syk, Dap12, SLP-76, and Vav3. In consequence, the cytoskeleton-organizing GTPase Rac transits from its inactive GDP-to its active GTPbound form. Absence of any component of this signaling pathway yields a common osteoclast phenotype with a deranged cytoskeleton and inability to spread (3) (4) (5) (6) (7) (8) . Macrophage colony-stimulating factor (M-CSF), which promotes osteoclastogenesis, also organizes the cytoskeleton of the mature bone resorptive cell by activating a signaling complex strikingly similar to that stimulated by ␣v␤3 (9, 10) .
In osteoclasts, ␣v␤3 mediates bone matrix recognition by binding ligands containing the RGD motif, but its ability to do so depends upon its configuration. Like integrins in other cells, ␣v␤3 in the osteoclast is maintained in a default low-affinity state by interactions between the ␣ and ␤ subunits (11, 12) . In its inactive conformation, the integrin heterodimer assumes a "bent" configuration in which the ␣ and ␤ intracellular domains interact via a membrane-proximal salt bridge. Upon integrin activation (i.e., increased affinity), the salt bridge is disrupted, the cytoplasmic tails separate, and the extracellular domain "straightens" to achieve a configuration permitting it to effectively bind ligand (13) .
Integrins are activated by two basic mechanisms (13) . Outside-in activation is achieved by initial ligand binding, which causes secondary conformational modifications, further enhancing the integrin's affinity. Outside-in conformational change can also be induced by chemicals or monoclonal antibodies (MAbs) prior to ligand binding. Inside-out activation, on the other hand, is an indirect process in which signals derived from an occupied receptor, typically that of a cytokine or growth factor, target the intracellular domain of an integrin. Such targeting of ␣v␤3 disrupts its salt bridge, separates its tails, and straightens the bent conformation of its external domain. The integrin is now positioned to bind ligand with high affinity and transmit matrix-derived signals, including those that organize the cytoskeleton.
Virtually all studies of integrin function in the osteoclast have focused on outside-in signaling. These experiments typically entail parachuting suspended, preterminally differentiated osteo clastic cells onto an ␣v␤3 ligand. This approach, however, does not mirror the resorptive process, in which osteoclasts are attached to the bone surface and constantly remodel their cytoskeleton as they move and degrade skeletal tissue. Nor does it mimic the physiological setting, in which cells are exposed to an array of cytokines and growth factors with the potential to alter integrin conformation.
Talin is a 270-kDa cytosolic adaptor protein that links ␤ integrins to the actin cytoskeleton and in so doing regulates multiple biological events such as macrophage participation in innate immunity (14) . In all cells studied, the interaction between talin and the ␤-integrin cytoplasmic domain is a final common and necessary step to inside-out integrin activation (15) . The high-affinity heterodimer now avidly binds extracellular ligand, which stimulates the transmission of intracellular signals, including those that organize the cytoskeleton. We find that M-CSF, which activates ␣v␤3 in osteoclasts, promotes the association of integrin with talin via Y747 in the ␤3 tail. Likely reflecting the inhibition of multiple integrins, we also note that conditional deletion of talin or its activator Rap1, in mature osteoclasts, arrests the resorptive function and increases bone mass substantially more than does absence of ␣v␤3. Additionally, osteoclast-specific talin deletion protects against estrogen-deficient osteoporosis and inflammatory osteolysis. Our observation that the pronounced bone-sparing effect of deleting talin or Rap1 occurs only in committed bone resorbing cells gives credence to a therapeutic strategy that avoids targeting early osteoclast precursors such as macrophages. Hence, the Rap1/talin signaling complex is a necessary component of physiological and pathological bone resorption.
MATERIALS AND METHODS
Mice. Generation of Tln1
fl/fl , ␤3 Y747A , and Rap1A fl/fl Rap1B fl/fl mice has been described (16) (17) (18) . CtsK cre/ϩ mice were provided by S. Kato (University of Tokyo, Tokyo, Japan) (19) . LysMCre-expressing mice were purchased from the Jackson laboratory. To obtain mice with talin1-deficient macrophages (LysM-TLN), Reagents. Recombinant murine M-CSF was obtained from R&D Systems (Minneapolis, MN). Glutathione S-transferase-receptor activator of nuclear factor B ligand (GST-RANKL) was expressed in our laboratory as described previously (6) . The sources of antibodies are as follows: mouse antitalin MAbs and antiactin antibodies were from Sigma (St. Louis, MO); antiphosphotyrosine MAb 4G10 was from Upstate (Charlottesville, VA); MAb 327, directed against the c-Src protein, was a gift of A. Shaw (Department of Pathology, Washington University School of Medicine, St. Louis, MO); rabbit anti-Src p-Y416 antibody and rabbit anti-␤3 integrin antibody were from Cell Signaling (Beverly, MA). Anti-NFATc1, anti-Rap1A, and anti-Rap1B antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). WOW1 ligand mimetic, which recognizes activated ␣v␤3 integrin, was provided by Sanford Shattil (University of California at San Diego). All other chemicals were obtained from Sigma.
Macrophage isolation and osteoclast culture. Primary bone marrow macrophages (BMMs) were prepared as described previously (6) , with slight modification. Marrow was extracted from femora and tibiae of 6-to 8-week-old mice with ␣-minimal essential medium (␣-MEM) and cultured in ␣-MEM containing 10% inactivated fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 g/ml streptomycin (␣-10 medium) with 1:10 CMG medium (conditioned medium containing 100 ng/ml mouse M-CSF) (20) on bacterial plastic dishes. Cells were incubated at 37°C in 6% CO 2 for 3 days and then washed with phosphate-buffered saline (PBS) and lifted with 1ϫ trypsin/EDTA (Invitrogen, Carlsbad, CA) in PBS. A total of 5 ϫ 10 3 cells were cultured in 200 l ␣-MEM containing 10% heat-inactivated FBS with 100 ng/ml GST-RANKL and 30 ng/ml of mouse recombinant M-CSF in 96-well tissue culture plates, some containing sterile bone slices. Cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity after 6 days in culture, using a commercial kit (Sigma 387-A, St. Louis, MO). For preosteoclast generation, 1.5 ϫ 10 6 BMMs were plated per 10-cm tissue culture dish and maintained in 30 ng/ml M-CSF and 100 ng/ml GST-RANKL for 3 days.
Actin ring and bone resorptive pit visualization. For actin ring staining, cells were cultured on bovine bone slices in the presence of M-CSF and RANKL for 6 days, after which cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100, rinsed in PBS, and immunostained with AlexaFluor 488-phalloidin (Molecule Probes). To quantitate resorption lacunae, cells were removed from bone slices with mechanical agitation. Bone slices were incubated with peroxidase-conjugated wheat germ agglutinin (WGA) (Sigma) for 1 h and stained with 3,3=-diaminobenzidine (Sigma).
Plasmids and retroviral transduction. Talin head constructs containing amino acids 1 to 433 were inserted into a pMX retrovirus vector in which the puromycin resistance sequence was replaced with one coding for blasticidin resistance. Generation of the pMX Turbo-Cre construct has been described (21) . It was transfected transiently into Plat-E packaging cells using FuGENE 6 transfection reagent (Roche). Virus was collected 48 h after transfection. BMMs were infected with virus for 24 h in the presence of 100 ng/ml M-CSF and 4 g/ml Polybrene (Sigma). Cells were selected in the presence of M-CSF and 1 g/ml blasticidin (Calbiochem) for 3 days prior to use as osteoclast precursors.
RNA preparation and RT-PCR analyses. Total RNA from cultured cells was isolated using the Total RNA Isolation kit (Sigma). For reverse transcription-PCR (RT-PCR) analysis, cDNAs were synthesized from 1 g of total RNA using reverse transcriptase and oligo(dT) primers in a volume of 20 l. The reaction mixture was adjusted to 100 l with Tris-EDTA (TE) buffer for PCR analysis. PCR was performed with 1 l of cDNA reaction mixture by using Platinum Pfx polymerase (Invitrogen, Carlsbad, CA) and appropriate primers in a volume of 50 l. The following primers were used: for Tln1, 5=-CAGAGGCCGTAGAAGACCTG and 3=-GGCTGGTGTTTGACTTGGTT; for Tln2, 5=-TGCAATGTGGTGAA GACCAT and 3=-GTGTCCGACCTGCTTCTAGC; and for b3, 5=-TTAC CCCGTGGACATCTACTA and 3=-AGTCTTCCATCCAGGGCAATA.
Western blotting and immunoprecipitation. Cultured cells were washed twice with ice-cold PBS and lysed in radioimmunoprecipitation assay (RIPA) buffer containing 20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM Na 3 VO 4 , 1 mM NaF, and 1ϫ protease inhibitor mixture (Roche). After incubation on ice for 10 min, cell lysates were clarified by centrifugation at 21.1 ϫ 10 3 g for 10 min. Forty micrograms of total lysates was subjected to 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride (PVDF) membranes. Filters were blocked in 0.1% casein in PBS for 1 h and incubated with primary antibodies at 4°C overnight followed by probing with fluorescence-labeled secondary antibodies (Jackson Lab). Proteins were detected with the Odyssey Infrared Imaging system (LI-COR Biosciences).
Rac1 and Rap1 activation assay. Preosteoclasts cultured on plastic dish or bone powder were stimulated with M-CSF and lysed, and Rac or Rap1 activity was determined by an effector domain, GST-fusion pulldown protocol using the EZ-detect Rac1 or Rap1activation kit (Pierce Biotechnology Inc.).
Medium CTx-1 assay. Macrophages were cultured on bone with 100 ng/ml RANKL and 1/100 volume CMG14-12 mouse M-CSF-producing cell line (20) supernatant for 6 days. The medium (␣-10) was changed 1 day before harvesting. Medium CTx-1 concentration was determined using the CrossLaps for Culture enzyme-linked immunosorbent assay (ELISA) kit (Nordic Bioscience Diagnosis A/S).
Phagocytosis assay. Thymocytes isolated from 4-week-old C57BL/6 mice were ␥-irradiated (1,400 rads) and cultured for 4 h to induce apoptosis. Thymocytes were 50 to 60% apoptotic as assessed by fluorescein isothiocyanate (FITC)-annexin V (BD Pharmingen) and 7-ADD (Calbiochem) staining (annexin V ϩ , 7-ADD Ϫ ). CFSE (5,6-carboxyfluorescein diacetate succinimidyl ester) (5 M) was used to label thymocytes for 10 min at room temperature. Labeled thymocytes were cocultured with macrophages at a ratio of 5:1 at 37°C. Cells were harvested with PBS-EDTA, stained with CD11b-allophycocyanin (CD11b-APC), and analyzed by flow cytometry. The percentage of phagocytosis was calculated as the fraction of CD11b ϩ cells that were positive in the FL1 channel. Serum osteocalcin measurements. Blood was collected retro-orbitally under anesthesia immediately prior to sacrifice. Serum osteocalcin levels were measured by ELISA (Biomedical Technologies Inc.). Plasma was obtained using plasma separator tubes with lithium heparin (Becton, Dickinson).
Microcomputed tomography (CT).
The trabecular volume in the distal femoral metaphysis or proximal tibia was measured using a Scanco CT40 scanner (Scanco Medical AG, Bassersdorf, Switzerland). A threshold of 250 was used for evaluation of all scans. Forty to 100 slices were analyzed, starting with the first slice in which condyles and primary spongiosa were no longer visible.
Calcein labeling. We injected calcein (Sigma) intraperitoneally at 7.5 mg/kg of body weight on days 7 and 2 before killing and then sectioned tibiae in methyl-methacrylate, which were analyzed using BioQuant OsteoII (BioQuant Image Analysis Corporation, Nashville, TN).
Serum transfer arthritis and histological analysis. Arthrogenic serum was obtained from K/B ϫ N mice (6 to 12 weeks old). Serum (100 l per mouse) was injected intraperitoneally on days 7 and 2 prior to sacrifice, whereas 100 l of PBS was administered to control animals. Five or more mice were used for each group. Paw thickness was measured daily.
Histology and histomorphometry. The tibiae of 2-month-old mice were fixed with 10% neutral buffered formalin, followed by decalcification in 14% EDTA for 10 days, paraffin embedding, and TRAP staining. Osteoclastic perimeters were measured and analyzed using BioQuant OsteoII (BioQuant Image Analysis Corporation, Nashville, TN) in a blinded fashion. Pit areas were measured with ImageJ.
Statistics. Statistical significance was determined using Student's t test. All experiments were performed at least twice.
RESULTS
M-CSF stimulates inside-out activation of the ␣v␤3 integrin in osteoclasts.
The fact that the signaling events by which M-CSF alters the osteoclast cytoskeleton are similar to those mediated by activated ␣v␤3 suggests a collaborative association. Confirming cytokine dependence on the integrin, M-CSF activation of Rac, the currently established most distal component of a canonical osteoclast cytoskeleton organizing complex, requires ␣v␤3 (Fig.  1A) . Establishing that the collaboration between ␣v␤3 and M-CSF reflects inside-out stimulation, the cytokine approximately doubles binding of WOW1, an ␣v␤3 ligand mimetic recognizing the activated integrin (Fig. 1B) . Furthermore, ␣v␤3 progressively associates with talin under the influence of M-CSF (Fig. 1C) , which also promotes talin migration from the podosome belt to cytokine-induced fillipodia (Fig. 1D) . ␤3 Y747 regulates talin-mediated cytoskeletal organization in osteoclasts. In other cells, optimal integrin activation requires talin recognition of ␤3 Y747 (17) . To determine if the same is true regarding the organization of the osteoclast cytoskeleton, bone marrow macrophages (BMMs) of knock-in mice bearing an alanine mutation of the residue were differentiated into osteoclasts in vitro. These cells, while normal in number, develop the same nonspread, crenated appearance extant in osteoclasts lacking the ␤3 integrin or its cytoskeleton-organizing effectors ( Fig. 2A and B ) (3) (4) (5) (6) (7) (8) . The abnormal appearance of these mutant cells does not represent arrested differentiation (Fig. 2C ). Like cultured ␤3-deficient osteoclasts, ␤3
Y747A cells generate actin rings, but their bone-resorptive activity is diminished ( Fig. 2D to G) .
Immunoblots of ␤3 immunoprecipitates document that M-CSF promotes talin association with wild-type (WT) ␤3, but not ␤3 Y747A (Fig. 2H ). In contrast to ␤3 Y747A osteoclasts, those expressing nonphosphorylatable ␤3
Y747F are essentially normal (22) . Like WT, ␤3
Y747F completely rescues ␤3 Ϫ/Ϫ osteoclasts, whereas ␤3
Y747A is unable to do so (Fig. 2I) . Thus, the mechanism by which ␤3 Y747A disrupts the cytoskeleton does not reflect arrested phosphorylation. Unlike what is seen in ␤3 Ϫ/Ϫ mice, no change in bone mass is evident in those bearing the ␤3 Y747A mutation at 6 months of age ( Y747A mice 4 weeks after ovariectomy. n ϭ 3 per group (*, P Ͻ 0.05; **, P Ͻ 0.01). Data are representative of at least 3 independent experiments (panels A through F and J through L) or 2 experiments (panels G and H). Numbers next to the gels represent molecular weights (in thousands). bone loss (Fig. 2K and L) (24) . Hence, ␤3 Y747 is essential for talin recognition by the integrin in osteoclasts.
Talin1-deficient osteoclasts are dysfunctional in vivo. In some cell types, talin2 can compensate for loss of talin1, but only talin1 is expressed by osteoclasts and their precursors (Fig. 3A ) (25, 26) . Therefore, we crossed mice with a conditional TLN1 allele to those expressing cathepsin K Cre (CtsK-Cre), which is active only in mature osteoclasts (19) (mice and osteoclasts with conditional deletion of TLN1 by CtsK-Cre are here referred to as CtsK-TLN1). In keeping with diminished resorptive activity, CtsK-TLN1 tibias and femurs are more radiodense than control tibias and femurs (Fig. 3B) . Similarly, trabecular bone mass and connectivity, determined by CT, is substantially increased in CtsK-TLN1 mice, as are volumetric and whole-body bone mineral density (BMD) (Fig. 3C to E) . Histological analysis confirms enhanced trabecular bone volume (BV/TV) in the mutant mice, despite normal numbers of osteoclasts ( Fig. 3F and G) . In contrast, histomorphometrically measured bone formation rates in Cre ϩ and Cre Ϫ mice are indistinguishable, as is the circulating osteoblast function marker osteocalcin (Fig. 4A to D) . In keeping with the skeletal consequences of talin deletion likely representing targeting of integrins in addition to ␣v␤3, CtsK-mediated deletion of only the latter does not impact bone mass in 8-week-old mice ( Fig.  4E and F) . Rap1-deficient osteoclasts are dysfunctional. Despite the relatively robust in vivo phenotype of CtsK-TLN1 mice, osteoclasts generated in vitro, for 5 days, are normal (Fig. 5A ). As seen in Fig.  5B , this unexpected phenomenon likely represents undiminished talin1 protein in these cells until 6 days of culture, the limit of their in vitro viability. To circumvent this limitation, we attempted, but failed, to delete the gene by transducing TLN1 fl/fl -bearing BMMs with Cre recombinase-transduced retrovirus (not shown). Based upon our previous experience that the success of in vitro Cremediated deletion is gene specific (21, 27) , we turned to Rap1, a Ras family GTPase, which in conjunction with Rap1 interacting adaptor molecule (RIAM) mediates talin/integrin recognition (28) . Like its effect on Rac (Fig. 1A) , M-CSF transits Rap1 to its active, GTP-bound form in prefusion osteoclasts (Fig. 5C ). In contrast to our attempts to target TLN1 fl/fl , Cre-mediated deletion of Rap1A fl/fl /Rap1B fl/fl in vitro was successful (Fig. 5D ). This exercise produced osteoclasts exhibiting the characteristic crenated appearance of those lacking integrin-activated, cytoskeleton-organizing molecules and with compromised bone-resorptive capacity (Fig. 5E to G) . In keeping with failed integrin activation, Cre ϩ Rap1 BMMs normally express differentiation markers under osteoclastogenic conditions (Fig. 4H) . Furthermore, liganding of ␣v␤3 does not phosphorylate its effector, Vav3 (Fig.  4I) , and M-CSF fails to prompt talin/␤3 association in the genedeleted, prefusion osteoclasts (Fig. 4J) .
Mice with Rap1-deficient osteoclasts are osteopetrotic. To determine the physiological relevance of Rap1 in osteoclasts, we crossed Rap1A fl/fl /Rap1B fl/fl mice to those expressing CtsK-Cre, generating animals whose in vivo phenotype mirrors those with conditional deletions of talin in that they develop a marked increase in bone mass despite an abundance of osteoclasts ( Fig. 6A to E) (mice and osteoclastic cells with conditional deletions of Rap1A/B by CtsK-Cre are here referred to as CtsK-Rap1). CtsK-induced loss of Rap1A/B is apparent within 3 days of exposing CtsKRap1 BMMs to M-CSF and receptor activator of nuclear factor B ligand (RANKL) (Fig. 6F ). In keeping with this early deletion, CtsKRap1 osteoclasts so generated have the crenated appearance characteristic of cytoskeletal disarray (Fig. 6G) . Thus, disruption of Rap1/ talin activity arrests integrin function in osteoclasts and inhibits their resorptive activity in vitro as well as in vivo.
Talin1-deficient osteoclast lineage cells are dysfunctional. Our previous experiments indicate that talin deletion late in osteoclastogenesis produces osteopetrosis in vivo but fails to yield an abnormal phenotype ex vivo. Given the success of in vitro Rap1 targeting, however, we reasoned that deleting TLN1 in early osteoclast lineage cells in vivo would obviate this limitation. To this end, we mated TLN1 fl/fl mice with those expressing Cre driven by the lysozyme M (LysM) promoter, expressed in all myeloid lineage cells (osteoclast lineage cells with conditional deletion of TLN1 by LysM-Cre are here referred to as LysM-TLN1). Talin1 is reduced by approximately 65% in LysM-TLN1 cells (Fig. 7A) , while expression of kindlin 3 mRNA, whose product binds and activates integrins, is intact (29) (30) (31) .
Similar to what is seen in CtsK-TLN1 mice, the number of osteoclasts in LysM-TLN1 animals is indistinguishable from that of the control (not shown). While the change is not as dramatic as that occurring in the context of CtsK-Cre, trabecular bone volume of LysM-TLN1 mice is also significantly increased (Fig. 7B) . Whereas cultured CtsK-TLN1 osteoclast lineage cells appear normal, LysM-TLN1 precursors cluster and largely fail to attach to and spread on substrate, features consistent with integrin dys- function (Fig. 7C) . The impaired attachment of LysM-TLN1 BMMs does not, however, promote apoptosis (data not shown).
BMMs do not express ␣v␤3 until they assume the osteoclast phenotype (32) . Talin1, however, also activates other integrins. In fact, M-CSF promotes talin association with the ␤1 subunit, which participates in osteoclast function, as documented by coimmunoprecipitation and confocal colocalization with exposure to the cytokine (30, 33) (Fig. 7D and E) .
LysM-Cre-mediated TLN1 deletion impairs osteoclast formation. To assess the phenotype of LysM-TLN1 osteoclasts, we treated Cre ϩ and Cre Ϫ BMMs with M-CSF and RANKL. While abundant, characteristic osteoclasts emerged in control cultures, only a few small, adherent, tartrate-resistant acid phosphatase (TRAP)-positive, talin1-deficient polykaryons appeared (Fig. 8A  and B ). These cells have abnormal cytoskeletons as evidenced by the presence of numerous minute, actin structures and a paucity of rings (Fig. 8C) . Attesting that these features represent failed inside-out integrin activation, they are virtually normalized by the outside-in stimulator, MnCl 2 (Fig. 8D) . In contrast, expression of the key osteoclast differentiation markers c-Src and NFATc1 is unaltered in RANKL-treated LysM-TLN1 cells, regardless of their capacity to adhere to substrate (Fig. 8E) . Similarly, LysM-Cremediated TLN1 deletion does not affect M-CSF-induced total tyrosine phosphorylation or signaling important for osteoclast differentiation and survival (Fig. 8F ). These observations indicate that osteoclast formation requires matrix adhesion by precursors, regardless of the expression of proteins that specifically regulate the cell's differentiation and function. This conclusion is in keeping with the failure of LysM-TLN1 BMMs to undergo multinucleation when exposed to IL-4 (Fig. 8G) .
As the adhesive properties of their precursors are compromised, one would expect mobilization of osteoclasts in response to a resorptive stimulus to be dampened in LysM-TLN1 mice. To determine if this is so, we supracalvarially injected Cre ϩ and Cre Ϫ mice with RANKL or PBS and stained their calvaria for TRAP activity (34) . Whereas control RANKL-injected calvaria contain numerous TRAP-rich resorption areas, they are much less abundant in those of LysM-TLN1 mice ( Fig. 9A and B) . Furthermore, calvarial mRNAs of the osteoclast markers cathepsin K and TRAP are induced by RANKL in WT but not LysM-TLN1 animals (Fig.  9C) . Thus, RANKL-enhanced osteoclast formation, in vitro and in vivo, requires progenitor cell talin expression. ␣v␤3, in the osteoclast, stimulates a cytoskeleton-organizing complex in which c-Src is a proximal effector (3, 10, 35) . To address this issue in the context of LysM-TLN1, we generated Cre ϩ and Cre Ϫ prefusion osteoclasts. They were lifted and either maintained in suspension or plated on ␣v␤3 ligand, which activates c-Src in control but not talin-deficient cells (Fig. 9D) . Tyrosine phosphorylation of specific components of LysM-TLN1 total cell lysate is also diminished.
To determine the impact of TLN1 deletion on integrin-directed movement, the lower surfaces of transwell filters were coated with the ␣v␤3 ligand vitronectin. LysM-TLN1 and control prefusion osteoclasts were added to transwells in which the lower chamber did or did not contain M-CSF. Neither genotype migrated toward ␣v␤3 ligand in the absence of M-CSF (Fig. 9E and  F) . In the presence of the activating cytokine, directed migration of both is increased but that of talin1-deficient cells is less than one-third of that of WT. Reflective of cytoskeletal dysfunction, the phagocytic capacity of LysM-TLN1 BMMs is also impaired (Fig. 9G) .
The talin head domain partially rescues talin1-deficient osteoclasts. Talin1 consists of a FERM domain-containing head linked to a long, flexible rod (36) . Retroviral expression of the talin1 head (talin ) in LysM-TLN1 BMMs prompts them to adhere to plastic and spread (Fig. 10A) . Furthermore, the tyrosine phosphorylation of adherent, head domain-transduced prefusion osteoclast lysate is more profound than that of Cre ϩ vector control (Fig. 10B) . The talin1 head substantially rescues the appearance and number of LysM-TLN1 TRAP-stained osteoclasts (Fig.  10C) but not their cytoskeletal abnormalities, as manifested by the persistence of numerous atypical, minute actin structures and a paucity of rings (Fig. 10D) .
Talin1-deficient osteoclasts protect against pathological bone loss. Reflecting diminished resorption, CT and histomorphometric analysis establishes that CtsK-TLN1 mice are substantially protected from bone loss following estrogen deprivation (Fig. 11A to C) . Similarly, the osteoclasts of CtsK-TLN1 mice with inflammatory arthritis, while abundant, are generally not juxtaposed to bone and exhibit the crenated appearance of those lacking integrin-activated cytoskeleton-organizing molecules, resulting in much less periarticular erosion ( Fig. 11D and E) . Thus, talin regulates osteoclast function in physiological and pathological circumstances.
DISCUSSION
There is compelling evidence that M-CSF and ␣v␤3 interdependently remodel the osteoclast cytoskeleton. For example, the cytokine needs ␣v␤3 to transit the cytoskeleton-organizing GTPase Rac to its GTP-bound state, and integrin-stimulated Rac, induced by adherence to bone, requires M-CSF. Hence, ␣v␤3 and M-CSF induction of their associated cytoskeleton-organizing signaling complexes are perhaps related by inside-out activation of the integrin. In fact, we previously determined that M-CSF activates a hybrid complex of murine ␣v and human ␤3 (11). We presently show that the same obtains, to a similar extent, in naïve WT cells. Having established that M-CSF is capable of activating ␣v␤3 in the bone-resorbing cell, we turned to the causal mechanisms and biological implications.
Talin recognizes the ␤3 integrin cytoplasmic domain by first binding a distal motif containing ␤3 Y747 . Alanine knock-in of this residue largely obviates talin1 recognition and prompts failure of osteoclast spreading in vitro (17) . In contrast to the alanine substitution, ␤3
Y747F has no effect on osteoclast formation and function (22) . In keeping with this observation, ␤3
Y747F rescues the ␤3 Ϫ/Ϫ osteoclast phenotype as effectively as the WT construct. Because YϾF substitution is more conservative than YϾA, the disruptive effect of ␤3 Y747A on talin1 recognition likely reflects the conformational change of the integrin rather than failed phosphorylation (25) .
To more directly determine the role of talin1 in osteoclast formation and function, we targeted the TLN1 fl/fl gene by CtsK-Cre, generating mice with a 5-fold increase in bone mass. In keeping with integrin dysfunction, CtsK-TLN1 osteoclasts are abundant but when stressed, such as in the context of inflammatory osteolysis, fail to spread or normally attach to bone.
Because CtsK is expressed late in osteoclastogenesis, Cre recombinase driven by the enzyme's promoter deletes target genes only in cells substantially committed to the osteoclast phenotype. To assess the impact of talin deletion throughout the osteoclastogenic process, we turned to mice expressing LysM-Cre, which is active in all myeloid cells. LysM-TLN1 BMMs and prefusion osteoclasts fail to attach to substrate, spread, or activate cytoskeleton-organizing molecules. LysM-TLN1 prefusion osteoclasts also do not migrate normally to ␣v␤3 ligand, another manifestation of defective integrin and cytoskeletal function. Failure of LysM-TLN1 cells to spread on substrate or migrate is not due to inadequate outside-in integrin activation, since the defect is rescued by MnCl 2 . Thus, the functional abnormalities of LysM-TLN1 osteoclast lineage cells likely reflect failed inside-out integrin activation.
Despite the robust in vivo skeletal phenotype of CtsK-TLN1 mice, osteoclasts generated in vitro from these animals are normal, reflecting the persistence of talin protein to the limits of cultured osteoclast viability. To circumvent this limitation, we attempted to delete TLN1 fl/fl in vitro with transduced Cre recombinase. While we have used this strategy successfully in other circumstances (21, 27) , we find it to be gene specific and were unsuccessful in the context of talin.
Talin contains two principal regions, the head and rod domains, which interact to autoinhibit the protein (13) . Rap1 and its binding partner, RIAM, activate talin1 by exposing its head, which then associates with cytoplasmic tails of ␤ integrins to disrupt their inactivating salt bridge and increase ligand affinity. The talin rod interacts with the cytoskeletal proteins, actin and vinculin. Given that Rap1 is essential for talin-mediated integrin activation, in other circumstances, we attempted to delete it in vitro by Cre transduction and were successful in generating osteoclasts with disorganized cytoskeletons. With the realization that Rap1 exerts effects other than talin activation, the identical skeletal appearance of mice lacking either gene provides compelling evidence that the normal appearance of osteoclasts derived from CtsK-TLN1 BMMs reflects failed deletion of the target protein.
The magnitude of skeletal resorption is reflective of the number of osteoclasts and the capacity of the individual cell to degrade bone. We have shown that the absence of ␣v␤3 or of members of its activated cytoskeleton-organizing complex arrests osteoclast function but not differentiation. In keeping with the essential role of talin in stimulating this complex, RANKL-and M-CSF-treated LysM-TLN1 BMMs express normal osteoclastogenic markers and activate relevant signaling molecules. On the other hand, mirroring the absence of ␣v␤3 (37), the number of osteoclasts derived from LysM-TLN1 BMMs in vitro is substantially reduced, a likely consequence of impaired motility and capacity to multinucleate. It is also reflected by impairment of LysM-TLN1 mice to mobilize osteoclasts in response to RANKL in vivo. The fact that two strains of poorly adherent precursors yield low numbers of osteoclasts in culture is consistent with the postulate that despite expression of normal differentiation markers, acquisition of the osteoclast phenotype requires matrix adherence and migration and is therefore impaired in the face of compromised integrin function.
Notwithstanding substantial deficiencies of osteoclast formation and function in vitro, the basal bone mass of LysM-TLN1 mice, albeit significantly increased, is not as abundant as that of CtsK-TLN1 animals. This difference, while enigmatic, may represent relative efficiencies of TLN1 deletion. Temporal differences in Cre expression may also contribute to this discrepancy, as we have observed similar inconsistencies in other circumstances involving the same two Cre-expressing mice (8) . Regardless of this conundrum, LysM-TLN1 mice provided us the means of assessing the role of talin's integrin-activating domain in osteoclasts. We find that expression of the talin1 head in LysM-TLN1 BMMs normalizes their capacity to adhere to matrix and spread. The transduced head also substantially increases the number of osteoclasts recruited by M-CSF and RANKL. However, consistent with the essential role of the talin1 rod in binding to cytoskeletal proteins (25) , neither osteoclast abundance nor appearance is completely rescued in LysM-TLN1 cells expressing the talin head alone. Thus, intact talin is required to functionally link the integrin to the osteoclast cytoskeleton.
The pragmatic aspect of our study relates to the fact that ␣v␤3 is the only integrin that has served as a clinically tested therapeutic target in the context of osteoporosis (38) . The bone-sparing effects of a small-molecule ␣v␤3 inhibitor are relatively modest and thus have not been further pursued. Because the osteopetrotic phenotypes of CtsK-TLN1, CtsK-Rap1, and kindlin3 Ϫ/Ϫ mice are more profound than of those of mice lacking the ␤3 integrin (23) or ␤3 Y747A , the therapeutic failure of ␣v␤3 inhibition likely reflects compensation by other integrins, such as those of the ␤1 family. Hence, targeting common motifs of numerous integrins that recognize essential activating molecules, such as talin, Rap1, or kindlin3, should be a more promising strategy for preventing and treating pathological osteolysis. Furthermore, our data establish that therapeutic targeting needs not be extant throughout osteoclastogenesis, which would impact other myeloid cells such as inflammatory macrophages. The fact that inhibition of integrin function late in the course of osteoclast development yields healthy mice substantially resistant to inflammatory osteolysis and estrogen-deficient osteoporosis buttresses this argument.
Thus, we propose the following model of M-CSF-mediated organization of the osteoclast cytoskeleton (Fig. 12) . Occupancy of c-Fms changes Rap1-GDP to its active, GTP-bound form. Rap1-GTP induces talin to associate with a variety of ␤ subunit cytoplasmic domains, thus transiting the integrins to their active, high-affinity conformation. Upon binding bone matrix-residing ligand, the integrin activates a canonical signaling complex, the most distal established member being Rac, thus organizing the osteoclast's cytoskeleton and enabling the cell to resorb bone.
